Whole brain volume changes in patients with progressive MS treated with cladribine.
about
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewClinical use of brain volumetry.Linking structural, metabolic and functional changes in multiple sclerosis.Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature.The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.Measuring brain atrophy in multiple sclerosis.Central nervous system atrophy and clinical status in multiple sclerosis.Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Chemotherapeutics in the treatment of multiple sclerosis.Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.Magnetic resonance imaging of multiple sclerosis.Head circumference as a useful surrogate for intracranial volume in older adults.Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?Cladribine for multiple sclerosis: review and current status.Cladribine: an investigational immunomodulatory agent for multiple sclerosis.Brain atrophy in multiple sclerosis: what we know and would like to know.Oral disease-modifying treatments for multiple sclerosis: the story so far.Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.Recent clinical trials and future therapies.New oral drugs for multiple sclerosis.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Disease-modifying treatments for progressive multiple sclerosis.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Cladribine in aggressive forms of multiple sclerosis.EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis.The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.Immunotherapy of multiple sclerosis.
P2860
Q26782408-D8AC0C64-12B5-4D5A-9805-D40A02B00972Q30582479-7CE212AA-3C78-4708-94F5-85B5B7DA5D5CQ30654880-A6E1EF00-3C54-4160-A74E-7BDAA1DF629AQ30739162-89734609-15A3-424B-A954-056FFD2BED57Q30953733-558A62D4-7B92-4FB5-9963-2066FD72EE82Q30983016-76D70F48-C0BD-4864-8C7D-EA2D88DB95E8Q31014025-8ECA4E75-83E7-4A09-8A20-F3E589DA484DQ31027953-F88661C5-0E09-4417-AB45-9FED2FC024FFQ31108858-9C1C2DC5-C8B4-4A12-9A6D-D4A6B608587CQ33204392-0352FD6D-6F32-4964-A42A-2EEFC708C1F7Q33204393-FF23675F-6CA2-4A9D-A6D9-7178CEEDE18DQ33289264-7523DC2D-5E28-42DA-BC37-B6F326A46DC2Q34153221-6E762820-FFFA-4EAF-B7AD-AB74DC18E432Q34237823-5B842B4A-D2FE-45BD-AE0A-ABB90196A00EQ34409536-93155DCC-CE42-446B-98EF-268097AAD42DQ34590775-5B65FFF7-3023-430F-843F-6F3E20477CE2Q34630494-C987A180-4D07-4CFE-B599-9764F41DF2EFQ34965696-2E6C89B5-1F6F-43B9-B8E4-2D930DE6E7C6Q35859512-446D7D05-CFDF-47F9-9A58-D602A51CE819Q36198757-44C020FC-E65C-4E30-8508-463B242B1FD5Q36307847-47A91C0F-15E6-46BD-9783-85D63DB78B5DQ36598122-B9CB2030-4382-44C4-A1B8-B8AEFE247983Q36722172-468E2B6D-2278-4C83-B2B2-3C4DEF2FB210Q36830152-16A97042-3433-4196-91A0-0389BCF08007Q37304222-D7956D92-5CB5-481C-B5EC-92917069D7CEQ37419072-9D3EBBE1-D1E6-45F5-A0F3-B33296E80B92Q37625921-C933C24E-7D6D-4990-ACC2-AE63E46F105AQ38101003-55445948-02FE-4268-BFDB-038B46581D37Q38142030-3FA17E63-A09F-4D59-9364-AA57FB72892DQ38375605-9725D812-D897-4D18-87E1-5F6B8E9EB244Q48150889-B65A1BBF-0D8E-4EA5-AB5D-DC0F97CFB7C2Q48565199-E6E7621F-7CF9-4972-872B-58888DCBDB2EQ50766232-5D8D8A93-9540-4D77-8D3D-D3A6F2E18F1BQ54502086-FD1E7CE4-8D72-4F17-AB3E-2012B2C958E1
P2860
Whole brain volume changes in patients with progressive MS treated with cladribine.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Whole brain volume changes in patients with progressive MS treated with cladribine.
@en
Whole brain volume changes in patients with progressive MS treated with cladribine.
@nl
type
label
Whole brain volume changes in patients with progressive MS treated with cladribine.
@en
Whole brain volume changes in patients with progressive MS treated with cladribine.
@nl
prefLabel
Whole brain volume changes in patients with progressive MS treated with cladribine.
@en
Whole brain volume changes in patients with progressive MS treated with cladribine.
@nl
P2093
P356
P1433
P1476
Whole brain volume changes in patients with progressive MS treated with cladribine.
@en
P2093
P304
P356
10.1212/WNL.55.11.1714
P407
P577
2000-12-01T00:00:00Z